Tech Company Financing Transactions
Transave Funding Round
Transave closed a $2.7 million funding round on 6/30/2007. Investors included F-Prime Capital.
Transaction Overview
Company Name
Announced On
6/30/2007
Transaction Type
Venture Equity
Amount
$2,684,000
Round
Undisclosed
Investors
F-Prime Capital (Robert Weisskoff)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11 Deer Park Drive 117
Monmouth Junction, NJ 08852
USA
Monmouth Junction, NJ 08852
USA
Phone
Website
Email Address
Not Recorded
Overview
TRANSAVE is a biotechnology company whose mission is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Whitten
Chief Financial Officer
Michio Soga
Chief Medical Officer
Renu Gupta
Chief Technical Officer
Walter Perkins
Vice President
Eric Dadey
VP - Operations
Nicholas Gurreri
Browse more venture capital transactions:
Prev: 6/30/2007: Seeo venture capital transaction
Next: 6/30/2007: Apogee Photonics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs